Effects of Synthetic Salmon Calcitonin Therapy in Children with Osteogenesis Imperfecta

Rebelo, Irene; Pereira‐da‐Silva, Luís; Blanco, Julieta; Monteiro, M. E. Sacramento; Ferreira, N. Cordeiro

doi:10.1177/030006058901700415

Cited by 11 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…During the 1980s, calcitonin was used to treat children and adults with OI in a number of centers (2,4,6,7,87,88). Conflicting results have been obtained; Nishi and colleagues (87) treated 10 children over a period of 10 yr using initially porcine and subsequently salmon calcitonin, either subcutaneously or nasally and continuously or intermittently.…”

Section: Calcitoninmentioning

confidence: 99%

Osteogenesis imperfecta

Bishop

2004

Clinic Rev Bone Miner Metab

View full text Add to dashboard Cite

| Skeletal deformity and bone fragility are the hallmarks of the brittle bone dysplasia osteogenesis imperfecta. The diagnosis of osteogenesis imperfecta usually depends on family history and clinical presentation characterized by a fracture (or fractures) during the prenatal period, at birth or in early childhood; genetic tests can confirm diagnosis. Osteogenesis imperfecta is caused by dominant autosomal mutations in the type I collagen coding genes (COL1A1 and COL1A2) in about 85% of individuals, affecting collagen quantity or structure. In the past decade, (mostly) recessive, dominant and X-linked defects in a wide variety of genes encoding proteins involved in type I collagen synthesis, processing, secretion and post-translational modification, as well as in proteins that regulate the differentiation and activity of bone-forming cells have been shown to cause osteogenesis imperfecta. The large number of causative genes has complicated the classic classification of the disease, and although a new genetic classification system is widely used, it is still debated. Phenotypic manifestations in many organs, in addition to bone, are reported, such as abnormalities in the cardiovascular and pulmonary systems, skin fragility, muscle weakness, hearing loss and dentinogenesis imperfecta. Management involves surgical and medical treatment of skeletal abnormalities, and treatment of other complications. More innovative approaches based on gene and cell therapy, and signalling pathway alterations, are under investigation. NATURE REVIEWS | DISEASE PRIMERS VOLUME 3 | ARTICLE NUMBER 17052 | 1 PRIMER © 2 0 1 7 M a c m i l l a n P u b l i s h e r s L i m i t e d , p a r t o f S p r i n g e r N a t u r e . A l l r i g h t s r e s e r v e d .In this Primer, we provide an overview of epidemio logy, genetics and pathophysiology of osteogenesis imperfecta, as well as diagnosis and management. EpidemiologyStudies from Europe and the United States have found a birth prevalence of osteogenesis imperfecta of 0.3-0.7 per 10,000 births 5,6 . These birth cohort analyses reflect moresevere types of osteogenesis imperfecta and do not include moresubtle types that become apparent after birth. A populationbased study that used the Danish National Patient Register found an annual incidence of osteogenesis imperfecta of 1.5 per 10,000 births between 1997 and 2013 (REF. 7). Population surveys in countries with comprehensive medical databases, such as Finland, estimated a prevalence of about 0.5 per 10,000 individ uals 8 , with most having phenotypically milder osteo genesis imperfecta type I and type IV (BOX 1; TABLE 1). Because these birth cohort and population surveys are based on clinical findings and tend to find mutu ally exclusive populations, a reasonable estimate of the incidence of osteogenesis imperfecta is about 1 per 10,000 individuals. Most patients are heterozygous for mutations in COL1A1 or COL1A2. No difference in the prevalence between sexes was reported.Approximately 90% of the 3,000 individuals whose mutations have ...

show abstract

Section: Calcitoninmentioning

confidence: 99%

Osteogenesis imperfecta

Bishop

2004

Clinic Rev Bone Miner Metab

View full text Add to dashboard Cite

show abstract

“…Calcitonin may be helpful in the prevention of GC‐induced osteoporosis and in children with OI 19–23 . However, conflicting results with no benefits were also reported 24,25 .…”

Section: Clinical Management Of Osteoporosis In Childrenmentioning

confidence: 99%

Clinical Management of Childhood Osteoporosis

Chan

Bishop

2002

Int J Clinical Practice

View full text Add to dashboard Cite

SUMMARYA current working definition of osteoporosis in children is ‘fragility fractures in association with low bone mass’. This review illustrates the determinants of bone mass and fracture risk. We elucidate the pathophysiology and causes of osteoporosis in various childhood disorders, with a particular focus on the commonest iatrogenic problem, glucocorticoid‐induced osteoporosis. We discuss clinical evaluation, investigation and multidisciplinary management including lifestyle advice, diet, physiotherapy and occupational therapy, drug treatments and monitoring for children with osteoporosis. We also emphasise the important concepts of bone mass assessment and interpretation in children.

show abstract

“…CT is also thought to exert a direct or indirect stimulatory effect on the osteoblasts, although this action is still poorly under stood [9], It has been used to treat senile and postmeno pausal osteoporosis [9], Paget's disease [10], osteogenesis imperfecta [11][12][13] and idiopathic juvenile osteoporosis [14], but has never been studied in thalassemic patients with osteoporosis. The purpose of this study was to evalu ate the effects of CT treatment in (3-thalassemia major patients.…”

Section: Introductionmentioning

confidence: 99%

Effects of Calcitonin Therapy on Osteoporosis in Patients with Thalassemia

Canatan

Akar

Arcasoy³

1995

Acta Haematol

View full text Add to dashboard Cite

The aim of this study was to evaluate the effects of calcitonin (CT) treatment on bone pain, osteoporosis, bone fractures and blood chemistry in thalassemic patients. Twenty-four patients with an age range of 10-24 years were included, 14 of whom received 100IU CT and 250 mg calcium 3 times a week. The others (n = 10) were followed up as a control group with only routine thalassemia therapy. After 1 year of treatment, bone pain disappeared and radiological signs of osteoporosis had improved significantly (p < 0.01) in the treatment group. CT has no important side effects.

show abstract

Effects of Synthetic Salmon Calcitonin Therapy in Children with Osteogenesis Imperfecta

Cited by 11 publications

References 10 publications

Osteogenesis imperfecta

Osteogenesis imperfecta

Clinical Management of Childhood Osteoporosis

Effects of Calcitonin Therapy on Osteoporosis in Patients with Thalassemia

Contact Info

Product

Resources

About